These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 18997134)
1. Hiccups and dopamine. Stegmeier-Petroianu A; Petroianu GA Am J Health Syst Pharm; 2008 Nov; 65(22):2092-4. PubMed ID: 18997134 [No Abstract] [Full Text] [Related]
2. Hiccups in Parkinson's disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature. Lertxundi U; Marquínez AC; Domingo-Echaburu S; Solinís MÁ; Calvo B; Del Pozo-Rodríguez A; García M; Aguirre C; Isla A Eur J Clin Pharmacol; 2017 Sep; 73(9):1159-1164. PubMed ID: 28600702 [TBL] [Abstract][Full Text] [Related]
3. Hiccups associated with non-ergoline dopamine agonists in Parkinson's disease. Coletti Moja M Mov Disord; 2010 Jul; 25(9):1292. PubMed ID: 20310014 [No Abstract] [Full Text] [Related]
5. Hiccups associated with dopamine agonists in Parkinson disease. Sharma P; Morgan JC; Sethi KD Neurology; 2006 Mar; 66(5):774. PubMed ID: 16534128 [No Abstract] [Full Text] [Related]
6. Dopamine agonists in early therapy for Parkinson disease: promise and problems. Tanner CM JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895 [No Abstract] [Full Text] [Related]
7. Alopecia induced by dopamine agonists. Tabamo RE; Di Rocco A Neurology; 2002 Mar; 58(5):829-30. PubMed ID: 11889256 [No Abstract] [Full Text] [Related]
8. Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone? Fernandez HH; Merello M Lancet Neurol; 2010 Jun; 9(6):556-7. PubMed ID: 20452824 [No Abstract] [Full Text] [Related]
9. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation. Kovacs N; Janszky J; Nagy F Drugs Aging; 2011 Feb; 28(2):161-2. PubMed ID: 21275441 [No Abstract] [Full Text] [Related]
11. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Senol MG; Togrol RE Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893 [No Abstract] [Full Text] [Related]
12. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease. Lyons KE; Pahwa R Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728 [TBL] [Abstract][Full Text] [Related]
13. Pramipexole and ropinirole for Parkinson's disease. Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824 [No Abstract] [Full Text] [Related]
14. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629 [TBL] [Abstract][Full Text] [Related]
15. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823 [TBL] [Abstract][Full Text] [Related]